Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on RVNC. HC Wainwright restated a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a research report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Mizuho cut their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Finally, Barclays dropped their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $3.06 on Friday. The stock has a market capitalization of $319.43 million, a price-to-earnings ratio of -1.59 and a beta of 0.81. The firm’s 50 day simple moving average is $4.08 and its 200-day simple moving average is $4.50. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. Analysts anticipate that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Certuity LLC purchased a new position in Revance Therapeutics in the second quarter valued at approximately $26,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Revance Therapeutics in the 2nd quarter valued at $33,000. Hsbc Holdings PLC acquired a new stake in Revance Therapeutics during the 2nd quarter worth $38,000. FORA Capital LLC purchased a new stake in Revance Therapeutics in the third quarter valued at $54,000. Finally, Creative Planning acquired a new position in Revance Therapeutics in the third quarter valued at $56,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.